Herantis Pharma Oyj (HEL:HRTIS)
Finland · Delayed Price · Currency is EUR | Market Cap | 44.79M +32.3% |
| Revenue (ttm) | n/a |
| Net Income | -6.62M |
| EPS | -0.28 |
| Shares Out | 26.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,778 |
| Average Volume | 25,846 |
| Open | 1.690 |
| Previous Close | 1.690 |
| Day's Range | 1.622 - 1.780 |
| 52-Week Range | 1.220 - 3.870 |
| Beta | 0.59 |
| RSI | 38.12 |
| Earnings Date | Aug 20, 2026 |
About Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland. [Read more]
Financial Performance
Financial StatementsNews
Herantis Pharma Oyj Earnings Call Transcript: H2 2025
HER-096 advanced through phase 1b with strong safety, brain penetration, and biomarker results, positioning for a phase two efficacy trial in Parkinson's disease. Financial position improved with grants and fundraising, but an additional EUR 20–25 million is needed to fully fund the next phase.
Herantis Pharma Oyj Phase 1b Biomarker Data Transcript
Herantis Pharma Oyj Phase 1b Biomarker Data Transcript
Herantis Pharma Oyj Transcript: Study Result
HER-096 demonstrated clear biological activity in Parkinson's patients, with dose-dependent effects on proteostasis, mitochondrial function, and oxidative stress pathways. These biomarker findings support the drug's mechanism, reduce risk for Phase 2, and strengthen partnering prospects.
Herantis Pharma Oyj Transcript: Study Result
HER-096 phase I-B trial in Parkinson's patients met safety and PK endpoints, with most adverse events being mild injection site reactions and no drug-related serious events. PK data support twice-weekly dosing, and biomarker analysis is ongoing to inform phase II design and partnering.
Herantis Pharma Oyj Earnings Call Transcript: H1 2025
HER-096, a potential first-in-class disease-modifying therapy for Parkinson's, advanced through phase I-B with top-line data expected by mid-October. Financials show increased R&D-driven loss and a strengthened cash position, but phase II requires new funding or partnerships.
Herantis Pharma Oyj Earnings Call Transcript: H2 2024
HER-096, a novel peptide for Parkinson's, showed strong safety and brain penetration in early trials, with phase 1b data expected in Q3 2025. Over EUR 6 million in non-dilutive funding was secured, and the cash runway extends into Q2 2026.
Herantis Pharma Oyj Transcript: R&D Day 2024
HER-096, a novel therapy for Parkinson's, is advancing through Phase Ib trials with strong preclinical and clinical safety data, targeting both symptomatic and disease-modifying effects. The program is well-funded, supported by major foundations, and is actively preparing for Phase II and partnering opportunities.
Herantis Pharma Oyj Earnings Call Transcript: H1 2024
HER-096 shows strong preclinical and early clinical promise for Parkinson's, with robust funding and external validation supporting ongoing trials. Current cash will fund phase Ib, but more capital is needed for phase II. The market for disease-modifying therapies is expected to grow significantly.